Neoadjuvant treatment in human epidermal growth factor receptor 2-positive breast cancer.
- Author:
Yinhua LIU
1
;
Shiwei LIU
2
;
Email: CONGZHONGFEIXIANG@163.COM.
;
Hong ZHANG
1
;
Ling XU
1
;
Ting LI
1
;
Xuening DUAN
1
Author Information
1. Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
2. Breast Disease Center, Peking University First Hospital, Beijing 100034, China
- Publication Type:Journal Article
- MeSH:
Breast Neoplasms;
Humans;
Neoadjuvant Therapy;
Prognosis;
Receptor, ErbB-2
- From:
Chinese Journal of Surgery
2015;53(12):901-904
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most prevalent malignancy among females worldwide. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer represents a subtype with aggressive behavior, poor response to treatment and unfavorable prognosis. Anti-HER2-based neoadjuvant treatment has improved clinical outcomes of patients with HER2-positive disease. Pathological complete response (pCR) after neoadjuvant treatment indicates a favorable prognosis. With the development of HER2-targeted therapy and neoadjuvant treatment, numerous studies focus on the predictive factors of pCR or therapeutic resistance of anti-HER2 therapy. Identification of novel predictive factors in HER2-positive breast cancer, such as tumor-infiltrating lymphocytes, will be helpful for clinical decision.
